πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 82 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11634688

Methods and compositions for inducing hematopoietic cell differentiation

Fate Therapeutics, Inc. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11617793

Anhydrous sodium thiosulfate and formulations thereof

Fennec Pharmaceuticals, Inc. Β· Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11510984

Anhydrous sodium thiosulfate and formulations thereof

Fennec Pharmaceuticals, Inc. Β· Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11413309

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. Β· Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11406646

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acc

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11365394

Enhanced immune effector cells and use thereof

Fate Therapeutics, Inc. Β· Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11352607

Genomic engineering of pluripotent cells

Fate Therapeutics, Inc. Β· Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11291728

Anhydrous sodium thiosulfate and formulations thereof

Fennec Pharmaceuticals, Inc. Β· Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11224624

Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior an

The Regents of the University of California Β· Granted Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11162075

Methods and compositions for inducing hematopoietic cell differentiation

Fate Therapeutics, Inc. Β· Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11162076

Methods and compositions for inducing hematopoietic cell differentiation

Fate Therapeutics, Inc. Β· Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11135244

Stem cell culture media and methods of enhancing cell survival

Fate Therapeutics, Inc. Β· Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11096964

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. Β· Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11072781

Genomic engineering of pluripotent cells

Fate Therapeutics, Inc. Β· Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11052118

Enhanced stem cell composition

Fate Therapeutics, Inc. Β· Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11006626

Compounds for protection of cells

Sulfateq B.V. Β· Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10980838

Methods of treating ischemia

Fate Therapeutics, Inc. Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10954529

Minimal volume reprogramming of mononuclear cells

Fate Therapeutics, Inc. Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10947505

Methods and compositions for inducing hematopoietic cell differentiation

Fate Therapeutics, Inc. Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10927346

Enhanced immune effector cells and use thereof

Fate Therapeutics, Inc. Β· Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10906928

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Atea Pharmaceuticals, Inc. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10894804

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Atea Pharmaceuticals, Inc. Β· Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10858628

Methods and compositions for inducing hematopoietic cell differentiation

Fate Therapeutics, Inc. Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10851412

Cell potency assay for therapeutic potential

Fate Therapeutics, Inc. Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted